Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer WithEGFRMutations-Reference-Cited by-同舟云学术

Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer WithEGFRMutations

Published:2012-09-20 Issue:27 Volume:30 Page:3330-3336
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Moran Teresa¹,Sequist Lecia V.²

Affiliation:

1. Catalan Institute of Oncology, Hospital Germans Trias i Pujol and Universitat Autonoma de Barcelona, Barcelona, Spain; Massachusetts General Hospital, Boston, MA

2. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.43.1858

Reference65 articles.

1. Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

2. Non–Small Cell Lung Cancer

3. Untangling the ErbB signalling network

4. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

5. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thoracic imaging;Clinical PET/MRI;2023

2. Tyrosine Kinase Receptors in Oncology;International Journal of Molecular Sciences;2020-11-12

3. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer;Cancer Chemotherapy and Pharmacology;2019-04-29

4. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy;Targeted Oncology;2019-01-11

5. Toxicidad pulmonar con relación a terapia contra el receptor del factor epidérmico;Open Respiratory Archives;2019